MedTrace Logo

Buprenorphine Maintenance Dose Schedule and Treatment Setting - 2

NCT00000319 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-07-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy of treating opioid-dependent individuals with buprenorphine on a thrice-weekly schedule compared to daily dosing.

Conditions

  • Opioid-Related Disorders
  • Substance-Related Disorders

Interventions

DRUG

Buprenorphine

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Richard Schottenfeld, M.D. · Yale University

Study Design

Purpose
TREATMENT

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-06-30
Completion
2005-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000319 on ClinicalTrials.gov